BioAlliance Pharma:Combined Extraordinary and Ordinary General Meeting on July 27Th 2009

PARIS--(Business Wire)--
Regulatory News:

BioAlliance Pharma (Paris:BIO)

Procedures for obtaining preparatory documents

BioAlliance Pharma's shareholders are invited to attend the Combined
Extraordinary and Ordinary General Meeting to be held at 10.00 am on July 27th
2009 at the company's head office (49 Boulevard du Général Martial Valin,
F-75015 Paris, France).

The official notice of the Meeting will be published in the French Republic's
Bulletin des Annonces Légales Obligatoires ("Bulletin of Mandatory Legal
Announcements") and in an official journal of legal announcements on July 10th,
2009. The agenda, the draft resolutions and information on attendance and voting
procedures can be viewed on the company's web site at:

http://www.bioalliancepharma.com/eng/Investisseurs/Shareholders-Meetings

Documents related to the meeting will be made available to shareholders from
July 8th onwards, under the conditions set out in the current legislation.
Shareholders may, in accordance with Articles R.225-88 and R.225-89 of the
French Commercial Code, consult the afore-mentioned documents (together with the
information specified in Articles R.225-81 and R.225-83 of the said Code) at the
company's head office or request supply of the said documents and information by
post/mail to a duly indicated postal/mailing or electronic address by writing to
BioAlliance Pharma (Direction Financière - 49 boulevard du Général Martial
Valin, F-75015 Paris, France), faxing to +33 1 45 58 08 81 or sending an e-mail
to ag2009@bioalliancepharma.com.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a
company which develops and markets innovative products in France, especially in
the fields of opportunistic infections and chemotherapy complications. In areas
where medical needs are insufficiently met, our targeted approaches help
overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma`s ambition is to become a leading player in these fields by
coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at
http://www.bioalliancepharma.com.

BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
or
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com
or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com

Copyright Business Wire 2009